KD Pharma obtains Rohner AG’s manufacturing assets
Acquisition further develops KD Pharma’s CDMO capabilities
The KD Pharma Group has acquired the manufacturing assets of the former Rohner AG. The assets provide KD Pharma access to new technologies that will allow the company to grow its pharmaceutical contract development and manufacturing organization (CDMO) business. KD Pharma has also strengthened its CDMO team by hiring former Rohner staff.
“KD Pharma has all the technology, capacity and people to become an even larger player in the CDMO market,” said Oscar Groet, KD Pharma Group CEO. “Rohner was known for its unique chemical processes and technological capabilities, enabling it to manufacture difficult, multi-step pharmaceutical intermediates and APIs [active pharmaceutical ingredients]. This is a natural fit with our strategy to create health solutions and provide value to customers by utilizing a unique toolbox of technologies.”
The KD Pharma Group has an existing CDMO site in the UK, as well as a contract softgel manufacturing site in the US and omega-3 manufacturing sites in Norway and Germany, since it also develops products in the nutraceutical space.
Newron, Myung In Pharm Form Partnership Centered Around Treating Schizophrenia in South Korea
January 14th 2025The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.
